Status:
RECRUITING
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Chronic Lymphocytic Leukemia
CLL
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the fre...
Detailed Description
The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax ...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years old;
- chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
- refractory and/or relapsed disease during or after venetoclax treatment;
- tumor samples available.
- Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
- Patients must be able to express their opposition to be enrolled in this study, if need be.
- Patients must be affiliated at the French Social Security system
Exclusion
- Patients of their legal guardians refusing to participate
- \-
Key Trial Info
Start Date :
March 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05246345
Start Date
March 7 2022
End Date
March 1 2027
Last Update
January 9 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Amiens
Amiens, France
2
CHU de Besançon
Besançon, France
3
Hopital AVICENNE
Bobigny, France
4
CHU clermont-ferrand
Clermont-Ferrand, France